Acitretin is indicated for:
Irrespective of gender only Adults (18 years old or older)
Acitretin is indicated for:
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Acitretin is contraindicated in the following cases:
Existing data suggests that concurrent intake of acitretin with ethanol led to the formation of etretinate. However, etretinate formation without concurrent alcohol intake cannot be excluded. Therefore, since the elimination half-life of etretinate is 120 days the post-therapy contraception period in women of childbearing potential must be 2 years.
Acitretin is contra-indicated in patients with severe renal impairment.
Acitretin is contra-indicated in patients with severe hepatic impairment.
Low dose progesterone-only products (minipills) may be an inadequate method of contraception during acitretin therapy. Interactions with combined estrogen/progestogen oral contraceptives have not been observed.
Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated. Supplementary treatment with antibiotics such as tetracyclines is therefore contra-indicated.
Acitretin is lipophilic and passes into the breast milk. Patients must not breast-feed during treatment with acitretin.
Acitretin is highly teratogenic. Its use is contraindicated in women who might become pregnant during or within 2 years of the cessation of treatment. The risk of giving birth to a deformed child is exceptionally high if acitretin is taken before or during pregnancy, no matter for how long or at what dosage.
Acitretin is contraindicated in every woman of childbearing potential unless each of the following conditions is met:
Primary contraceptive method is a combination hormonal contraceptive product or an intrauterine device and it is recommended that a condom or diaphragm (cap) is also used. Low dose progesterone-only products (minipills) are not recommended due to indications of possible interference with their contraceptive effect.
For male patients treated with acitretin, available data, based on the level of maternal exposure from the semen and seminal fluid indicate a minimal, if any, risk of teratogenic effects.
An increased risk of hepatitis has been reported following the concomitant use of methotrexate and etretinate. Consequently, the concomitant use of methotrexate and acitretin should be avoided.
Concomitant administration of acitretin with other retinoids or Vitamin A is contra-indicated due to the risk of hypervitaminosis A.